NCT00372281 is a Phase 3 clinical trial of Cliavist in Spine Infection, sponsored by University Hospital, Strasbourg, France.

Who is sponsoring NCT00372281?

NCT00372281 is sponsored by University Hospital, Strasbourg, France.

What drugs are being tested in NCT00372281?

Interventions in NCT00372281: Cliavist.

What condition does NCT00372281 study?

NCT00372281 studies Spine Infection.

Is NCT00372281 still recruiting?

NCT00372281 is currently status unknown. Last updated 24 February 2009.

Last reviewed 2009-02-24 · How we verify

NCT00372281

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Cliavist Enhancement in Infectious and Degenerative Diseases of the Spine

Status unknown Phase 3 Last updated 24 February 2009

What this trial tests

Phase 3 trial testing Cliavist in Spine Infection in 40 participants. Status unknown.

Timeline

1 March 2007

Primary endpoint
1 August 2009

1 December 2009

Quick facts

Lead sponsor	University Hospital, Strasbourg, France
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	1 March 2007
Primary completion	1 August 2009
Estimated completion	1 December 2009
Sites	4 locations across France

Drugs / interventions tested

Cliavist — full drug profile →

Conditions studied

Spine Infection — all drugs for Spine Infection →

Sponsor

University Hospital, Strasbourg, France

Who can join

18 and older, any sex, with Spine Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

First MRI: performed immediately after gadolinium administration
Time frame: immediately after gadolinium administration
Second MRI: performed 24 hours after cliavist administration
Time frame: 24 hours after cliavist administration

Sponsor's own description

USPIO contrast enhancement results from intracellular trapping of the iron particles in reactive cells, especially macrophages. 17FDG-PET studies have demonstrated that macrophages are present in spine infectious diseases but are absent in spine degenerative diseases. The aim of this work is to compare the enhancement induced by CLIAVIST in both diseases. The absence of macrophages in degenerative lesions should help to differentiate them from infectious lesions, who should present contrast enhancement in relation to the presence of macrophages.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in magnetic nanoparticles for molecular medicine.
Yang X, Kubican SE, Yi Z, Tong S. · · 2025 · cited 8× · PMID 39846549 · DOI 10.1039/d4cc05167j

Verify or expand the search:

Other recruiting trials for Spine Infection

Currently open trials in the same condition.

NCT06284174 — Effectiveness of Povidone-Iodine Versus Chlorhexidine Gluconate Solutions in Reducing Microbial Contamination in Spinal · NA · recruiting

Other University Hospital, Strasbourg, France trials

Trials by the same sponsor.

NCT07418554 — Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Pla · Phase 3 · not yet recruiting
NCT07108582 — Reducing Chronic Pain After Lung Surgery: A Trial of Limiting NSAIDs During Recovery · Phase 3 · not yet recruiting
NCT07302646 — Optimizing Reduced-Flow, Low-Volume Contrast Protocols for Cerebral Angiography in Unruptured Aneurysms · NA · not yet recruiting
NCT07273968 — Clinical Study Evaluating the Effect of Virtual Reality on Reducing Patients' Anxiety During Wisdom Teeth Extraction · NA · not yet recruiting
NCT07214103 — Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulop · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00372281 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Strasbourg, France
Last refreshed: 24 February 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00372281.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing